# Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia

> **NCT07516561** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Apsen Farmaceutica S.A.** · enrollment: 336 (estimated)

## Conditions studied

- Alopecia, Androgenetic

## Interventions

- **DRUG:** APSMNF 1
- **DRUG:** APSMNF 2
- **DRUG:** Eniagor®

## Key facts

- **NCT ID:** NCT07516561
- **Lead sponsor:** Apsen Farmaceutica S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-07
- **Primary completion:** 2029-08-02
- **Final completion:** 2029-08-02
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07516561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07516561, "Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07516561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*